Literature DB >> 28643051

Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer.

John H Marks1, Elizabeth A Myers2, Erik L Zeger3, Albert S Denittis4, Mounica Gummadi2, Gerald J Marks2.   

Abstract

BACKGROUND: The challenge of performing a good total mesorectal excision (TME) dissection, particularly in the distal 1/3 of the rectum, has spurred interest in new techniques. Robotic surgery is advocated by some, and more recently, a "new" approach, the transanal total mesorectal excision, has been popularized to address this problem. While great interest in this technique exists, little long-term outcome data are available. We have been utilizing a transanal abdominal transanal approach to TME in order to facilitate the distal dissection, and here, we provide our long-term outcomes using this approach in the management of rectal cancer.
METHODS: From a prospectively maintained rectal cancer database, we identified 373 consecutive rectal cancers treated with sphincter preservation surgery through a combined transanal and abdominal approach to TME. Perioperative, pathological, and oncologic outcomes were analyzed.
RESULTS: Three hundred and seventy-three patients with rectal cancer underwent a transanally initiated TME with mean follow-up of 5.5 years. 91% of cancers were in the distal rectum. 68.9% were men and 53.2% of cancers were tethered or fixed on presentation. 97.7% received neoadjuvant radiotherapy (mean 5405 cGy, 5-fluorouracil based); average time from completion of neoadjuvant therapy to surgery was 11 weeks. 180 and 193 patients underwent completion of their operation through open and laparoscopic abdominal approaches. 96% of TME specimens were complete/near complete, 94% had a negative circumferential resection margin, and 98.6% had a negative distal margin. Perioperative morbidity and mortality rates were 13.4 and 0.3%. Overall local recurrence (LR), DM, and Kaplan-Meier 5-year actuarial survival were 7.4, 19.5, and 90%, respectively.
CONCLUSION: This is the first report of long-term data using a transanal approach to TME supporting this approach for rectal cancer. Our data with 5-year follow-up show that adequate distal and circumferential margins with very good-quality TME specimens, and a low risk for LR with excellent overall survival can be achieved using this technique. Our long-term results support the promising reports of early experiences in the literature.

Entities:  

Keywords:  APR; Laparoscopic rectal cancer; NOTES; Rectal cancer; Sphincter preservation; TATA; TME; Transanal TME (taTME)

Mesh:

Year:  2017        PMID: 28643051     DOI: 10.1007/s00464-017-5597-7

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  32 in total

Review 1.  What is the role for the circumferential margin in the modern treatment of rectal cancer?

Authors:  Iris D Nagtegaal; Phil Quirke
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

2.  DISCUSSION ON PROLAPSE OF THE RECTUM.

Authors:  W E Miles
Journal:  Proc R Soc Med       Date:  1924

3.  [Hybrid TAMIS total mesorectal excision. A new perspective in treatment of distal rectal cancer - Technique and results].

Authors:  A D Rink; D W Kauff; M Paschold; K-H Vestweber; H Lang; W Kneist
Journal:  Chirurg       Date:  2016-03       Impact factor: 0.955

4.  Sphincter-sparing surgery for adenocarcinoma of the distal 3 cm of the true rectum: results after neoadjuvant therapy and minimally invasive radical surgery or local excision.

Authors:  John Marks; George Nassif; Henry Schoonyoung; Al DeNittis; Eric Zeger; Mohammed Mohiuddin; Gerald Marks
Journal:  Surg Endosc       Date:  2013-09-21       Impact factor: 4.584

5.  Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.

Authors:  Pierre J Guillou; Philip Quirke; Helen Thorpe; Joanne Walker; David G Jayne; Adrian M H Smith; Richard M Heath; Julia M Brown
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

6.  Anatomical considerations for transanal minimal-invasive surgery: the caudal to cephalic approach.

Authors:  F Aigner; R Hörmann; H Fritsch; J Pratschke; A D'Hoore; E Brenner; N Williams; M Biebl
Journal:  Colorectal Dis       Date:  2015-02       Impact factor: 3.788

7.  Laparoscopic transanal abdominal transanal resection with sphincter preservation for rectal cancer in the distal 3 cm of the rectum after neoadjuvant therapy.

Authors:  J Marks; B Mizrahi; S Dalane; I Nweze; G Marks
Journal:  Surg Endosc       Date:  2010-04-23       Impact factor: 4.584

8.  Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): a stepwise description of the surgical technique with video demonstration.

Authors:  S Atallah; M Albert; T DeBeche-Adams; G Nassif; H Polavarapu; S Larach
Journal:  Tech Coloproctol       Date:  2013-02-02       Impact factor: 3.781

9.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

10.  "Down-to-Up" transanal NOTES Total mesorectal excision for rectal cancer: Preliminary series of 9 patients.

Authors:  Ricardo Zorron; Henrique N Phillips; Greg Wynn; Manoel P Galvao Neto; Djalma Coelho; Ricardo C Vassallo
Journal:  J Minim Access Surg       Date:  2014-07       Impact factor: 1.407

View more
  26 in total

1.  Transanal total mesorectal excision (taTME) in a single-surgeon setting: refinements of the technique during the learning phase.

Authors:  A Caycedo-Marulanda; G Ma; H Y Jiang
Journal:  Tech Coloproctol       Date:  2018-06-28       Impact factor: 3.781

2.  Trans-perineal minimally invasive surgery during laparoscopic abdominoperineal resection for low rectal cancer.

Authors:  Daiki Yasukawa; Tomohide Hori; Yoshio Kadokawa; Shigeru Kato; Yuki Aisu; Suguru Hasegawa
Journal:  Surg Endosc       Date:  2018-07-09       Impact factor: 4.584

3.  SSAT State-of-the-Art Conference: Advances in the Management of Rectal Cancer.

Authors:  Evie Carchman; Daniel I Chu; Gregory D Kennedy; Melanie Morris; Marc Dakermandji; John R T Monson; Laura Melina Fernandez; Rodrigo Oliva Perez; Alessandro Fichera; Marco E Allaix; David Liska
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

4.  A prospective study of health related quality of life, bowel and sexual function after TaTME and conventional laparoscopic TME for mid and low rectal cancer.

Authors:  Y Li; X Bai; B Niu; J Zhou; H Qiu; Y Xiao; G Lin
Journal:  Tech Coloproctol       Date:  2021-03-01       Impact factor: 3.781

Review 5.  Future Directions.

Authors:  António S Soares; Manish Chand
Journal:  Clin Colon Rectal Surg       Date:  2020-04-28

Review 6.  Transanal Surgery: A History of taTME Ancestry.

Authors:  Kevin M Izquierdo; Jean F Salem; Esther Cha; Ece Unal; John H Marks
Journal:  Clin Colon Rectal Surg       Date:  2019-11-07

7.  Transanal total mesorectal excision: 3-year oncological outcomes.

Authors:  S Ourô; D Albergaria; M P Ferreira; B Costeira; P Roquete; D Ferreira; R Maio
Journal:  Tech Coloproctol       Date:  2020-10-28       Impact factor: 3.781

8.  Short- and long-term outcomes of transanal versus laparoscopic total mesorectal excision for mid-to-low rectal cancer: a meta-analysis.

Authors:  Xuan Zhang; Yi Gao; XingLong Dai; HongTao Zhang; ZhongJun Shang; XinYi Cai; Tao Shen; XianShuo Cheng; Kun Yu; YunFeng Li
Journal:  Surg Endosc       Date:  2018-10-29       Impact factor: 4.584

Review 9.  Two-Year Follow-Up of the First Transanal Total Mesorectal Excision (TaTME) Case Performed in Community Hospital in Hawai'i: A Case Report and Literature Review.

Authors:  Victor Bochkarev
Journal:  Hawaii J Health Soc Welf       Date:  2021-07

10.  The risk factors of local recurrence and distant metastasis on pT1/T2N0 mid-low rectal cancer after total mesorectal excision.

Authors:  I-Li Lai; Jeng-Fu You; Yih-Jong Chern; Wen-Sy Tsai; Jy-Ming Chiang; Pao-Shiu Hsieh; Hsin-Yuan Hung; Yu-Jen Hsu
Journal:  World J Surg Oncol       Date:  2021-04-13       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.